Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection.

Frontiers in immunology - 1 Jan 2024

Liu Shengjiang, Chen Haifeng, Chen Xiangqun, Luo Ningguang, Peraramelli Sameera, Gong Xiaoming, Zhang Mingwei John, Ou Li

Abstract excerpt

Introduction: Angiotensin converting-enzyme 2 (ACE2) is an enzyme catalyzing the conversion of angiotensin 2 into angiotensin 1-7. ACE2 also serves as the receptor of several coronaviruses, including SARS-CoV-1 and SARS-CoV-2. Therefore, ACE2 could be utilized as a therapeutic target for treating these coronaviruses, ideally lacking enzymatic function. Methods: Based on structural analysis, specific mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to Antibodies, Neutralizing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19

Share to COVID-19 Drug Treatment

Share to HEK293 Cells

Share to Protein Binding

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 38646520
DOI: 10.3389/fimmu.2024.1365803
PMCID: PMC11032047

Genes

ACE2
SPR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection.PMID 38646520Read ↗

A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitroSemantic proximity Read ↗

Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.Semantic proximity Read ↗

ACE2-based decoy receptors for SARS coronavirus 2.Semantic proximity Read ↗

Potential COVID‐19 therapeutic approaches targeting angiotensin‐converting enzyme 2; An updated reviewSemantic proximity Read ↗

Computational and Experimental Identification of Potential Neutralizing Peptides Derived from Human ACE2 Against SARS-CoV-2 InfectionSemantic proximity Read ↗

David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitorsSemantic proximity Read ↗

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig.Semantic proximity Read ↗

Characterisation of a novel ACE2-based therapeutic with enhanced rather than reduced activity against SARS-CoV2 variantsSemantic proximity Read ↗

Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.Semantic proximity Read ↗

Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main ReceptorSemantic proximity Read ↗

Development of a mutant aerosolized ACE2 that neutralizes SARS-CoV-2 in vivo.Semantic proximity Read ↗

A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.